Orion (ORNBV) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
9 Jul, 2026Executive summary
All divisions delivered strong performance in Q2 and H1 2025, with significant growth in innovative medicines, especially NubeqaⓇ, and robust results across branded products, generics, and animal health.
Achieved key regulatory milestones, including FDA approval and CHMP recommendation for darolutamide in combination with ADT for metastatic hormone-sensitive prostate cancer.
Expanded research pipeline with new biologics expected to enter clinical stage within 12–24 months and new licensing agreements for cancer and Parkinson’s disease treatments.
Major R&D and business developments include a new Cambridge R&D center, expanded clinical trials, and leadership changes in key divisions.
EasyhalerⓇ peak sales potential upgraded to over EUR 300 million annually.
Financial highlights
Q2 2025 net sales rose 27% year-over-year to EUR 416.5 million; operating profit up 59% to EUR 104.6 million; operating margin at 25.1%.
H1 2025 net sales increased 21.1% to EUR 771.0 million; operating profit up 49.8% to EUR 182.5 million; H1 margin at 23.7%.
Q2 operating cash flow per share was EUR 0.57 (+189.7%); H1 at EUR 1.12 (+14.1%).
Royalties, especially from NubeqaⓇ, contributed almost EUR 46 million to operating profit.
H1 2025 profit for the period was EUR 143.8 million (+50.2%); basic EPS at EUR 1.02 (+50.0%).
Outlook and guidance
2025 net sales expected between EUR 1,630–1,730 million; operating profit guidance set at EUR 400–500 million.
Guidance range remains wide due to uncertainties in NubeqaⓇ royalties, timing of R&D expenses, and market dynamics.
R&D expenses expected to rise in H2 as projects progress; capital expenditure to remain at 2024 levels.
Outlook excludes potential milestone payments and acquisitions.
Latest events from Orion
- Nubeqa-led growth lifted 9M sales 24.1% and operating profit 65.2%.ORNBV
Investor presentation - Nubeqa-led Q3 growth lifted operating profit 73.5% and drove higher FY26 guidance.ORNBV
Q3 2026 - AGM approved a EUR 1.62 dividend, Board changes and authority to issue up to 14 million shares.ORNBV
AGM 2024 - Innovative Medicines and Nubeqa® fuel robust growth, with strong profits and global expansion.ORNBV
Investor presentation - Strong H1 2026 growth driven by Innovative Medicines and Nubeqa royalties; outlook raised.ORNBV
Q2 2026 - Net sales and profit surged in Q1, driven by NubeqaⓇ and Easyhaler®, with upgraded 2026 outlook.ORNBV
Q1 2026 - Net sales and profit surged on Nubeqa® milestones, prompting an upgraded 2024 outlook.ORNBV
Q3 2024 - Strong H1 growth and upgraded 2024 outlook driven by Nubeqa, Animal Health, and milestone deals.ORNBV
Q2 2024 - Growth driven by innovation, global expansion, and new biologics pipeline.ORNBV
CMD 2025